Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $24.8900 (3.02%) ($23.2800 - $24.9600) on Thu. Aug. 2, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.62% (three month average) | RSI | 34 | Latest Price | $24.8900(3.02%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.6% a day on average for past five trading days. | Weekly Trend | ADMS declines -5.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) ONLN(20%) IBB(19%) XOP(17%) IWM(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.31% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.31% (StdDev 2.62%) | Hourly BBV | 0 () | Intraday Trend | 4.1% | | | |
|
1 - 5 Day Possible Target | $16.09(-35.36%) | Resistance Level | $26.08 | 5 Day Moving Average | $24.53(1.47%) | 10 Day Moving Average | $25.7(-3.15%) | 20 Day Moving Average | $26.08(-4.56%) | To recent high | -23.8% | To recent low | 5.7% | Market Cap | $704m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |